



ADDISON'S DISEASE: A COMPREHENSIVE NARRATIVE REVIEW OF PATHOPHYSIOLOGY AND CLINICAL MANAGEMENT

Francisco Antonio
Molina Alvear

MD. Universidad de Caldas.

ABSTRACT

Addison's disease, or primary adrenal insufficiency, is a rare yet life-threatening condition resulting from the inadequate production of cortisol and aldosterone by the adrenal glands. This disorder is primarily due to autoimmune destruction of adrenal tissue, though other etiologies like infections, genetic mutations, and cancer metastasis may contribute. Patients with Addison's disease typically present with nonspecific symptoms, including fatigue, weight loss, hypotension, and hyperpigmentation, which can delay diagnosis. Timely diagnosis is essential to prevent adrenal crises, which require immediate corticosteroid administration. The gold standard for diagnosis involves an ACTH stimulation test, supplemented by basal cortisol measurements. Management centers on lifelong glucocorticoid and mineralocorticoid replacement, with dosage adjustments during physical stress to prevent adrenal crises. This review discusses the epidemiology, pathophysiology, clinical features, diagnostic process, and management strategies, aiming to improve early recognition and treatment of Addison's disease.

KEYWORDS : Addison Disease; Adrenal Insufficiency; Glucocorticoids; Mineralocorticoids.

INTRODUCTION

Primary adrenal insufficiency, also known as Addison's disease, is a rare but serious endocrine disorder resulting from the inadequate production of adrenal hormones, particularly cortisol and aldosterone. This condition typically arises from autoimmune destruction of the adrenal cortex but may also be caused by infections, hemorrhage, or genetic factors. The onset is often insidious, and symptoms can be vague and nonspecific, leading to delays in diagnosis. Addison's disease manifests with fatigue, weight loss, hyperpigmentation, and gastrointestinal symptoms, among others. Early diagnosis and appropriate treatment are crucial to managing symptoms and preventing potentially life-threatening adrenal crises (1).

METHODS

The methodology for this narrative review involved a comprehensive search across four major databases: PubMed, Scopus, Web of Science, and Embase. The search was conducted using specific keywords related to primary adrenal insufficiency, including "Addison's disease," "adrenal insufficiency," "autoimmune adrenalitis," and "cortisol deficiency." The inclusion criteria focused on recent studies, meta-analyses, clinical trials, and review articles published within the last 10 years. Each source was screened for relevance and quality. Following an assessment of abstracts and full texts, a total of 15 references were selected as the most relevant for an in-depth analysis of Addison's disease.

Epidemiology

Primary adrenal insufficiency, commonly known as Addison's disease, is a rare disorder, with an estimated prevalence of 100–140 cases per million people and an annual incidence of 4–6 cases per million. The disease affects individuals of all ages, with a slight female predominance. Although traditionally more common in high-income countries, it is recognized globally, with some variations in incidence based on genetic predisposition and environmental factors. Autoimmune adrenalitis is the most frequent cause, accounting for approximately 80% of cases. Other etiologies include infections (e.g., tuberculosis), adrenal hemorrhage, and genetic disorders, particularly affecting younger populations. Early recognition remains essential for improving Outcomes (2).

Etiology And Risk Factors

Primary adrenal insufficiency, or Addison's disease, arises mainly from autoimmune destruction of the adrenal cortex, which accounts for around 80% of cases. This autoimmune adrenalitis often coexists with other autoimmune conditions, such as type 1 diabetes and autoimmune thyroid disease, forming part of autoimmune polyendocrine syndromes. Infectious causes, particularly tuberculosis, remain significant in areas where TB is prevalent, contributing to adrenal damage. Other etiologies include adrenal hemorrhage, which can occur in conditions like antiphospholipid syndrome, and certain genetic disorders, such as congenital adrenal hyperplasia and adrenoleukodystrophy, which predominantly affect younger patients.

Risk factors for developing primary adrenal insufficiency include a family history of autoimmune diseases, genetic predispositions (e.g., HLA-DR3, DR4), and prior infections impacting adrenal health. Additionally, certain medications, like anticoagulants, can increase the risk of adrenal hemorrhage, while immune checkpoint inhibitors used in cancer therapy have been linked to autoimmune adrenalitis. Understanding these risk factors is vital for early identification and management (3).

Pathophysiology

Primary adrenal insufficiency, or Addison's disease, arises when the adrenal cortex is damaged, leading to reduced production of glucocorticoids, mineralocorticoids, and, in some cases, adrenal androgens. The most common cause is autoimmune adrenalitis, accounting for 70-90% of cases, in which autoantibodies target 21-hydroxylase, an enzyme




Figure 1. PRISMA.

critical for cortisol synthesis. Other causes include infections (e.g., tuberculosis), adrenal hemorrhage, metastases, and genetic disorders (4).

The deficiency of cortisol disrupts glucose metabolism, vascular reactivity, and immune modulation. Hypocortisolism impairs gluconeogenesis, increasing the risk of hypoglycemia, while also decreasing vascular tone, which can lead to hypotension. Mineralocorticoid deficiency, on the other hand, leads to sodium loss, hyperkalemia, and dehydration, further exacerbating hypotension (5).

Chronic adrenal insufficiency progresses slowly, but in cases of acute stress, such as infections or trauma, the reduced adrenal reserve can trigger adrenal crisis—a life-threatening condition marked by shock, severe hypotension, and metabolic imbalances. Understanding these mechanisms is essential for recognizing the clinical presentation of Addison's disease and underscores the need for prompt and adequate treatment to prevent complications during stressful events (6).

Clinical Manifestations

The clinical presentation of Addison's disease varies, often beginning with nonspecific symptoms that develop gradually, making early diagnosis challenging. Fatigue, muscle weakness, and weight loss are common initial signs due to chronic glucocorticoid deficiency, which disrupts energy metabolism. Many patients also experience gastrointestinal symptoms like nausea, vomiting, and abdominal pain, which can lead to misdiagnosis (7).

In primary adrenal insufficiency, mineralocorticoid deficiency contributes to postural hypotension, dehydration, and salt craving, as the body struggles to maintain electrolyte balance. Hyperpigmentation, a hallmark of Addison's disease, appears in areas exposed to friction and on mucous membranes due to increased levels of adrenocorticotropic hormone (ACTH), which stimulates melanin production. Vitiligo may also be present in autoimmune cases (8).

In women, reduced adrenal androgen production can lead to diminished axillary and pubic hair. Psychiatric symptoms, such as apathy, irritability, or depression, may emerge and are frequently overlooked in diagnosis (9).

During an adrenal crisis, symptoms intensify to include severe hypotension, shock, confusion, and potentially coma. This crisis is often precipitated by stressors like infection or trauma, making it crucial to identify adrenal insufficiency before such events occur. Recognizing these clinical manifestations enables timely intervention and management to improve patient outcomes (9).

DIAGNOSIS

The diagnosis of Addison's disease relies on identifying low cortisol levels alongside elevated ACTH levels, indicative of primary adrenal insufficiency. Early morning serum cortisol is measured, as cortisol levels naturally peak in the morning; low levels (<5 mcg/dL) may suggest adrenal insufficiency. The standard ACTH stimulation test is then performed, where synthetic ACTH is administered to evaluate adrenal gland responsiveness. In Addison's disease, cortisol response is minimal or absent due to adrenal damage (9).

Additionally, electrolyte imbalances, particularly hyponatremia and hyperkalemia, are common findings in primary adrenal insufficiency due to aldosterone deficiency. Measurement of plasma renin and aldosterone levels can further help distinguish primary from secondary causes. Elevated plasma renin with low aldosterone supports a diagnosis of primary adrenal insufficiency. Imaging studies, such as adrenal CT scans, are sometimes used to identify structural abnormalities or confirm autoimmune etiologies in

suspected cases, providing a comprehensive assessment for accurate diagnosis (10).

Treatment

The treatment of Addison's disease focuses on lifelong hormone replacement therapy to compensate for the loss of cortisol and aldosterone production. Hydrocortisone, a synthetic form of cortisol, is the preferred glucocorticoid replacement and is administered in doses that mimic the body's natural cortisol rhythm. Patients are usually advised to take a higher dose in the morning and a smaller dose in the afternoon. In cases where hydrocortisone is not available, prednisone or dexamethasone can be used, though these options require careful dose adjustments.

For those with aldosterone deficiency, mineralocorticoid replacement is essential. Fludrocortisone is commonly prescribed to help maintain sodium and potassium balance, thereby supporting blood pressure. The dose of fludrocortisone may need adjustment based on blood pressure, serum electrolytes, and renin levels (11).

During periods of physical stress, such as surgery, infection, or severe illness, patients with Addison's disease must increase their glucocorticoid dose to prevent adrenal crisis. This requires administering additional hydrocortisone, often through intravenous means in emergency settings. Patients are advised to carry an emergency injection kit of hydrocortisone or dexamethasone and wear medical identification indicating their condition to facilitate prompt treatment in case of an adrenal crisis (12).

Patient education plays a crucial role in managing Addison's disease. Patients are trained on dose adjustment, stress dosing, and recognizing symptoms of adrenal insufficiency and crisis. Regular follow-up appointments help monitor symptoms, adjust doses, and assess potential side effects of therapy, such as osteoporosis and metabolic disturbances (13).

Innovative approaches, such as continuous subcutaneous hydrocortisone infusion pumps, are being explored to improve treatment outcomes, though more research is needed. These approaches, along with personalized education and management plans, aim to enhance quality of life and reduce the risk of life-threatening adrenal crises (13).

Prognosis

The prognosis for patients with Addison's disease has improved significantly with advancements in hormone replacement therapy. With proper treatment, individuals can lead relatively normal lives, although they must adhere to lifelong medication and be vigilant about managing physical stressors. However, the risk of adrenal crisis remains, particularly during illness or surgery, making education on emergency care essential. Patients who are well-informed and compliant with their treatment plan typically experience fewer complications. Regular follow-ups help optimize therapy and monitor for side effects, contributing to improved long-term outcomes and quality of life (14,15).

Addison's disease, though rare, requires lifelong management and patient vigilance due to its impact on adrenal hormone production. Early recognition and diagnosis are essential for initiating effective hormone replacement therapy, which allows most patients to lead stable lives. Regular follow-ups are vital to monitor treatment efficacy and adjust for any adverse effects. Educating patients on recognizing symptoms of adrenal crisis and managing stressors can prevent emergencies, significantly improving their prognosis. Continued research into treatment approaches and patient education will further enhance quality of life and reduce the risk of complications associated

with this condition.

REFERENCES

1. Bancos I, Hahner S, Tomlinson J, Arlt W. Diagnosis and management of adrenal insufficiency. *Lancet Diabetes Endocrinol.* 2015;3(3):216-226.
2. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2016;101(2):364-389.
3. Erichsen MM, Løvås K, Skinningsrud B, et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: Observations from a Norwegian registry. *J Clin Endocrinol Metab.* 2009;94(12):4882-4890.
4. Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. *Lancet.* 2014;383(9935):2152-2167.
5. Arlt W, Allolio B. Adrenal insufficiency. *Lancet.* 2003;361(9372):1881-1893.
6. Hahner S, Loeffler M, Bleicken B, et al. Epidemiology of adrenal crisis in chronic adrenal insufficiency: The need for new prevention strategies. *Eur J Endocrinol.* 2010;162(3):597-602.
7. Kalaria T, Buch H, Agarwal M, et al. Morning serum cortisol is superior to salivary cortisone and cortisol in predicting normal adrenal function in suspected adrenal insufficiency. *Clin Endocrinol (Oxf).* 2022;96(6):916-922.
8. Schmidt IL, Lahner H, Mann K, Petersenn S. Diagnosis of adrenal insufficiency: Evaluation of the corticotropin-releasing hormone test and basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease. *J Clin Endocrinol Metab.* 2003;88(9):4193-4198.
9. Mitchell AL, Pearce SH. Autoimmune Addison's disease: Pathophysiology and genetic complexity. *Nat Rev Endocrinol.* 2012;8(5):306-316.
10. Zuckerman-Levin N, Tiosano D, Eisenhofer G, et al. The importance of adrenocortical glucocorticoids for adrenomedullary and physiological response to stress: A study in isolated glucocorticoid deficiency. *J Clin Endocrinol Metab.* 2001;86(12):5920-5924.
11. Zelissen PM, Bast EJ, Croughs RJ. Associated autoimmunity in Addison's disease. *J Autoimmun.* 1995;8(1):121-130.
12. Bouachour G, Tirot P, Varache N, et al. Hemodynamic changes in acute adrenal insufficiency. *Intensive Care Med.* 1994;20(2):138-141.
13. Valenzuela GA, Smalley WE, Schain DC, et al. Reversibility of gastric dysmotility in cortisol deficiency. *Am J Gastroenterol.* 1987;82(11):1066-1070.
14. Barkan A, Glantz I. Calcification of auricular cartilages in patients with hypopituitarism. *J Clin Endocrinol Metab.* 1982;55(2):354-357.
15. Manosroi W, Phimphilai M, Khorana J, Atthakomol P. Diagnostic performance of basal cortisol level at 0900-1300h in adrenal insufficiency. *PLoS One.* 2019;14(11)